Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modelling Ben-Fillippo KrippendorffDiego A. OyarzúnWilhelm Huisinga Original Paper Open access 08 March 2012 Pages: 125 - 139
Dose correction for the Michaelis–Menten approximation of the target-mediated drug disposition model Xiaoyu YanWojciech Krzyzanski OriginalPaper 04 January 2012 Pages: 141 - 146
Population pharmacokinetic modelling of S-warfarin to evaluate the design of drug–drug interaction studies for CYP2C9 Kerenaftali KleinIvelina GueorguievaLeon Aarons Original Paper 21 January 2012 Pages: 147 - 160
Population pharmacodynamic modeling of various extended-release formulations of methylphenidate in children with attention deficit hyperactivity disorder via meta-analysis Holly KimkoEkaterina GibianskyFrank Wiegand Original Paper 22 January 2012 Pages: 161 - 176
Evaluation of IPPSE, an alternative method for sequential population PKPD analysis B. D. LacroixL. E. FribergM. O. Karlsson Original Paper 21 January 2012 Pages: 177 - 193
First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development Ashley StrougoThomas EissingJan Freijer Original Paper Open access 05 February 2012 Pages: 195 - 203
Moxifloxacin versus placebo modeling of the QT interval Philippe GrosjeanSaïk Urien Original Paper 17 February 2012 Pages: 205 - 215
Population pharmacokinetic and pharmacodynamic modeling of MNRP1685A in cynomolgus monkeys using two-target quasi-steady-state (QSS) model Yan XinHong XiangShuang Bai Original Paper 01 March 2012 Pages: 217 - 226